Sky Labs expects to become profitable in 2028 as partnerships with Omron Healthcare and Otsuka Pharmaceutical support expansion outside South Korea. Chief executive Byeong-hwan Lee said at an IPO briefing in Seoul's Yeouido on the 21st that the company's CART BP had been adopted at all five of Korea's top hospitals and 38 of its 47 tertiary general hospitals as of June this year. CART BP Pro is a cuffless blood pressure monitor worn like a ring, with approvals from Korea's Ministry of Food and Drug Safety and under Europe's CE-MDR medical-device regulation. It is also the first cuffless monitor to receive an insurance reimbursement rate from the Health Insurance Review and Assessment Service for 24-hour ambulatory blood-pressure testing. Sky Labs has completed discussions with the U.S. Food and Drug Administration (FDA), the U.S. medical-products regulator, on a clinical-trial protocol and expects approval around the end of 2027 after local trials. More than half of the company's roughly 5 billion won in first-half revenue, or about 2.6 billion won, came from overseas. Sky Labs is targeting 10.2 billion won in revenue this year, 18.8 billion won next year and 38.7 billion won in revenue with 4.7 billion won in operating profit in 2028, after projected operating losses of 15.4 billion won and 10.4 billion won respectively. Its 2030 targets are 78 billion won in revenue and 30.5 billion won in operating profit. The company plans to offer 2 million shares at 13,000 to 16,000 won each, raising 26 billion to 32 billion won, and list on KOSDAQ in early September after subscriptions on the 26th and 27th.